(ARGX) |
| 0 (0%) 01-14 13:16 |
| Open: | |
| High: | |
| Low: | |
| Volume: | 0 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | |
| Industry: | |
| Sector: |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 904.79 |
| Resistance 1: | 853.56 |
| Pivot price: | 821.47 |
| Support 1: | 770.67 |
| Support 2: | 641.20 |
| 52w High: | |
| 52w Low: |
Financials
| EPS | 23.350 |
| Book Value | 99.660 |
| PEG Ratio | 0.00 |
| Gross Profit | 32.808 |
| Profit Margin (%) | 41.63 |
| Operating Margin (%) | 30.40 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Company news
Wed, 14 Jan 2026
New Analyst Forecast: $ARGX Given $1000 Price Target - Quiver Quantitative
Wed, 14 Jan 2026
Wedbush Reiterates Outperform Rating for ARGX with $1000 PT | AR - GuruFocus
Tue, 13 Jan 2026
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $900 to $1,006 - 富途牛牛
Tue, 13 Jan 2026
Argenx Vyvgart label expansion gets FDA priority review (ARGX) - Seeking Alpha
Tue, 13 Jan 2026
Seronegative myasthenia patients in FDA priority review of VYVGART - Stock Titan
Mon, 12 Jan 2026
How Investors Are Reacting To argenx (ENXTBR:ARGX) Leadership Shift And Expanding Immunology Pipeline - Yahoo Finance
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
